|  |
| --- |
|  |
| Book Name: | [**Medical Science: Trends and Innovations**](https://www.bookpi.org/bookstore/product/medical-science-trends-and-innovations-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_4695** |
| Title of the Manuscript:  | **Risk Factors and Treatment Outcome Analysis Associated with Second-Line Drug-Resistant Tuberculosis** |
| Type of the Article | **Book Chapter** |

**Special note:**

**A research paper already published in a journal can be published as a Book Chapter in an expanded form with proper copyright approval.**

**Source Article:**

**This chapter is an extended version of the article published by the same author(s) in the following journal.**

**Journal of Respiration, 2(1): 1-12, 2022.**

**DOI:** [**https://doi.org/10.3390/jor2010001**](https://doi.org/10.3390/jor2010001)

|  |
| --- |
| PART 1: Comments |
|  | Reviewer’s comment**Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | **Cases of DR-TB is high in India and equally there is emergence and prevalence of resistance against second line drugs. It is imperative to know the pattern of drug resistance in this part of the world so that we can analyse the risk and outcome of treatment and can apply the knowledge for bringing new drugs and effective implementation of programme for the elimination of TB and betterment of mankind.** |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | **Beyond the First Line: Uncovering Risk Factors and Treatment Outcomes of Second Line Drug Resistant Tuberculosis** |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **1. It is mentioned that 258 pulmonary TB samples were already declared resistant to first line drugs,than how come upon genotypic test 7 were declared sensitive,and 251 resistant. What was the criteria of declaraing resistance of initial 258 cases?** **2. You have mentioned 200 cases of INH monoresistantce out of 258 total cases (77.5%) which is unacceptably high agaist the national average(16% of all as per PMDT,2021)** |  |
| **Is the manuscript scientifically, correct? Please write here.**  | 1. **Definition of Pre XDR and XDR TB as mentioned in the manuscript is older,obsolete and now no longer used.( Refer PMDT 2021).**
2. **In material and method section 2.1 you should mention the details of the guideline used.(NTEP Year)**
3. **In 2.3 treatment outcome analysis you have mentioned All Oral Longer Bedaquiline Based Regimen which is as per PMDT 2021, but definition of Pre XDR and XDR TB is used as per older guidelines.**
4. **In 2.3 treatment outcome analysis, definition of Cured and Treatment completed is old and has been changed now.**
5. **In Figure 1 of flow diagram, if 42 cases have been declared MDRTB than how come 37 cases among them be PAN sensitive? Similarly with H-mono resistance and R mono resistance. Please explain.**
 |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.****-** | **1. National guidelines for management of Drug resistant TB, November 2024.****2. Guidelines for programmatic management of Drug Rsistant Tuberculosis in India,PMDT, March,2021** |  |
| Is the language/English quality of the article suitable for scholarly communications? | Needs correction of some typoerror. |  |
| Optional/General comments | There is some basic flaw in the manuscript writing which needs to be addressed as mentioned above. |  |

|  |
| --- |
| **PART 2:**  |
|  | Reviewer’s comment | Author’s comment *(if agreed with the reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?**  | *(If yes, Kindly please write down the ethical issues here in detail)* |  |

**Reviewer details:**

**Manish Shankar, Indira Gandhi Institute of Medical Sciences, India**